医生调查：医生真正希望从 MSL 获得什么以及哪些方面可以改进

背景

随着 MSL 在製定治疗领域策略方面发挥的策略性和影响力日益凸显，製药公司必须了解医疗保健专业人员 (HCP) 在与 MSL 的互动中最希望获得什么，并衡量 MSL 满足其需求的有效性。例如，自 COVID-19 疫情以来，混合互动模式增加，MSL 和 HCP 对此是否意见一致？

本报告对法国、德国、义大利、西班牙、英国和美国的 417 名医生进行了调查，以了解他们对与 MSL 互动的感受以及如何改进。这些医生来自五个专科：心臟病学、内分泌学、神经病学、肿瘤学和风湿病学。

关键问题解答

• 1. 整体而言，您对目前与製药公司 MSL（注意：非销售人员）的互动满意度如何？
• 2. 您希望如何与药厂 MSL（注意：非销售人员）沟通？
• 3. 您认为 MSL 主动向您和您的诊所提供的科学和产品资讯对您以及您的诊所有何影响？
• 4. 您希望多久与药厂 MSL（注意：非销售人员）互动一次？
• 5. 您希望进行哪些改变，以最大程度地改善您与製药公司 MSL（注意：非销售人员）互动的体验？

The backstory:

As the MSL role is increasingly recognised as more strategic and influential in shaping therapeutic area strategies, it is vital for pharmaceutical companies to understand what healthcare professionals (HCPs) want most from MSL interactions and to gauge how effectively MSLS are meeting their needs. For instance, are MSLs and HCPs on the same page when it comes to the hybrid engagement models that have increased since the COVID-19 pandemic?

The physician view:

FirstWord recently polled 417 doctors from France, Germany, Italy, Spain, the UK and US to gain an inside look at how they feel about their MSL interactions and how they could be improved. These physicians work across five specialties: cardiology, endocrinology, neurology, oncology and rheumatology.

Key Questions Answered:

• 1. How satisfied are you overall with your current interactions with medical science liaison (MSL) representatives from pharmaceutical companies? (note: not sales representatives)
• 2. How would you prefer to communicate with MSLs from pharmaceutical companies? (note: not sales representatives)
• 3. Typically, how useful is the unsolicited scientific and product information MSLs provide to you and your practice?
• 4. Please indicate how often you would like to interact with MSLs from pharmaceutical companies? (note: not sales representatives).
• 5. What one change would most improve your interaction experience with MSLs from pharmaceutical companies? (note: not sales representatives)

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.